SCHEMBL6250262

SCHEMBL6250262

CC(Nc1ncnc2cc(C(=O)N3CCCCC3CN3CCN(C)CC3)c(Cl)cc12)c1nc2cc(Cl)ccc2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.38
UTS2R Q9UKP6 4/20 0.36
PRCP P42785 4/20 0.35
HSD11B1 P28845 1/20 0.34
SOS1 Q07889 1/20 0.34
MET P08581 2/20 0.34
GRM5 P41594 1/20 0.34
OPRK1 P41145 2/20 0.33
EGFR P00533 1/20 0.33
KDR P35968 1/20 0.33
NPC1 O15118 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
NFKB1 P19838 1/20 0.33
CYP2C19 P33261 1/20 0.33
OPRD1 P41143 1/20 0.33
HIF1A Q16665 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4150807 1.00 HRH3 (0.38) HRH3UTS2RPRCPHSD11B1SOS1
SCHEMBL4150809 1.00 HRH3 (0.38) HRH3UTS2RPRCPHSD11B1SOS1
SCHEMBL8324096 0.95 HRH3 (0.41) HRH3UTS2RHSD11B1METGRM5
SCHEMBL4162554 0.95 HRH3 (0.41) HRH3UTS2RHSD11B1METGRM5
SCHEMBL4162552 0.95 HRH3 (0.41) HRH3UTS2RHSD11B1METGRM5
SCHEMBL3002850 0.95 HRH3 (0.43) HRH3UTS2RSOS1METOPRK1
SCHEMBL4880042 0.95 HRH3 (0.43) HRH3UTS2RSOS1METOPRK1
SCHEMBL4143885 0.90 HSD11B1 (0.37) HRH3PRCPHSD11B1SOS1GRM5
SCHEMBL8321495 0.90 HSD11B1 (0.37) HRH3PRCPHSD11B1SOS1GRM5
SCHEMBL4144399 0.90 HSD11B1 (0.43) PRCPHSD11B1SOS1GRM5NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-07-16 US disclosed
US-7429597-B2 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-09-30 US disclosed
US-7429597-B2 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-09-30 US disclosed
EP-1583757-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2005-10-12 EP disclosed
WO-2004058743-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-15 WO disclosed
WO-2004058743-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS F12, F11, F2 HRH3 457/4885UTS2R 627/4885PRCP 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.